Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Core Insights - Palisade Bio is focusing on developing PALI-2108 as a potential leader in treating Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD) due to the significant unmet need for more effective treatment options [1][3] Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [2][5] - The company aims to transform the treatment landscape through a targeted approach with its innovative therapeutics [5] Expert Insight - Dr. Brian Feagan, a leading expert in IBD and FSCD, discussed the challenges of current therapies and emphasized the need for treatments that effectively address both inflammation and fibrosis [3] - He highlighted PALI-2108's localized approach, which aims to minimize class-associated side effects while maintaining anti-inflammatory and anti-fibrotic efficacy [3]